September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
NAION: Light At the End of the Tunnel?
Author Affiliations & Notes
  • Tassos Georgiou
    Ophthalmos Research and Educational Institute, Nicosia, Cyprus
  • YAO-TSENG WENG
    Institute of Medical Science, Hualien, Taiwan
  • Panagiotis Kolovos
    Ophthalmos Research and Educational Institute, Nicosia, Cyprus
  • Maria Kalogerou
    Ophthalmos Research and Educational Institute, Nicosia, Cyprus
  • Katerina Prokopiou
    Ophthalmos Research and Educational Institute, Nicosia, Cyprus
  • Anastasia Neokleous
    Ophthalmos Research and Educational Institute, Nicosia, Cyprus
  • CHIN-TE HUANG
    Buddhist Tzu Chi General Hospital, Institute of Eye Research, Hualien, Taiwan
  • Rong-Kung Tsai
    Buddhist Tzu Chi General Hospital, Institute of Eye Research, Hualien, Taiwan
  • Footnotes
    Commercial Relationships   Tassos Georgiou, Tassos Georgiou (P); YAO-TSENG WENG, None; Panagiotis Kolovos, None; Maria Kalogerou, None; Katerina Prokopiou, None; Anastasia Neokleous, None; CHIN-TE HUANG, None; Rong-Kung Tsai, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 5069. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Tassos Georgiou, YAO-TSENG WENG, Panagiotis Kolovos, Maria Kalogerou, Katerina Prokopiou, Anastasia Neokleous, CHIN-TE HUANG, Rong-Kung Tsai; NAION: Light At the End of the Tunnel?. Invest. Ophthalmol. Vis. Sci. 2016;57(12):5069.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Non-arteritic anterior ischemic optic neuropathy (NAION) is a visually disabling disease due to primary damage of retinal ganglion cells (RGC). Currently there is no effective treatment. High doses of omega-3 (ω-3) fatty acids demonstrated a promising effect in other types of ocular pathologies. Therefore, the purpose of this study was to investigate the therapeutic effect of ω-3 using a rat model of anterior ischemic optic neuropathy (rAION) and examine its potential neuro-regenerative and/or neuro-protective properties on RGCs.

Methods : RAION was induced using laser-induced photoactivation of intravenously administered Rose Bengal in the optic nerve head of adult male Wistar rats. Daily gavage administration of fish oil (1 g/day eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)) or phosphate buffered saline (PBS) was given either pre- or post-rAION induction. The animals were assigned to the following treatment groups (n=6/group): PBS treatment, ω-3 pre-treatment (3 days pre-rAION induction), ω-3 immediate treatment (day 0 to day 2 post-rAION induction), ω-3 delayed treatment (day 3 to day 5 post-rAION induction) and ω-3 continuous treatment (day 3 pre-rAION to day 7 post-rAION induction). Gas chromatographic analysis was used to assess the level of blood arachidonic acid (AA)/EPA following treatment on day 0, 3 and 7. Animals used in this study underwent flash visual-evoked potentials (FVEP) to assess visual function and were euthanized 4 weeks post-infarct. Density of RGCs was counted using Fluoro-gold retrograde labeling. Two-tailed Student’s t-test was used for statistical analysis.

Results : The RGCs’ density (1922 ± 361, 1576 ± 313 and 2720 ± 618 vs 744 ± 183, p < 0.05) and P1-N2 amplitude (48.2 ± 2.4, 44.3 ± 6.1 and 54.2 ± 2.1 vs 25.0 ± 1.3, p < 0.05) were found significantly higher in the groups of immediate, delayed and continuous treatment, compared to that of PBS group. Analysis of blood fatty acids showed that the AA/EPA ratio was greatly reduced on day 3 and day 7 post-treatment compared to day 0 (2.88 ± 0.07, 1.69 ± 0.16 vs 5.87 ± 0.22, p < 0.0001).

Conclusions : Our findings suggest that administration of ω-3 fatty acids has a neuro-regenerative effect in the rAION as demonstrated both by the RGCs density and FVEP analysis. This might indicate a remarkable turning point in the current treatment approach of patients with NAION; however further work is needed in order to elucidate the underlying mechanism of this effect.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

 

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×